Navigation Links
GenoSpace Expands Its Management Team by Appointing Daniel Meyer as Chief Financial Officer
Date:3/28/2013

CAMBRIDGE, Mass., March 28, 2013 /PRNewswire/ -- GenoSpace, LLC, a company that builds information systems capable of storing and integrating genomic information and other health data for clinical care and advanced research, today announced the addition of Daniel Meyer as Chief Financial Officer.

(Logo: http://photos.prnewswire.com/prnh/20130328/NE84802LOGO)

"We have been working with Dan in an advisory relationship since forming the company, and are pleased to be able to bring him on full time," stated John Quackenbush , PhD., CEO of GenoSpace. "The GenoSpace team has produced incredible successes since we launched and we are getting excellent feedback from our customers and users at clinical labs and research institutions. Our ability to build the senior management team reflects the rapidly growing scale of our business and quality of our pipeline."

Mr. Meyer has spent his entire career in life sciences entrepreneurship, venture capital and investment banking. He covered the healthcare portfolios at Arboretum Ventures and Point Judith Capital, where he focused on investments in life science tools, medical devices, healthcare information technology and services. Prior to his work investing in early stage companies, Mr. Meyer was a member of the health care investment banking team at Credit Suisse First Boston. He was also a co-founder and the General Manager of a medical device startup from inception through prototype development. Mr. Meyer holds a B.A. in Mathematics and Economics from Middlebury College and an M.B.A. from the Tuck School of Business at Dartmouth.

About GenoSpace
At GenoSpace, we are Digital Architects of Genomic Medicine™. GenoSpace is a Cambridge, Massachusetts-based company that has developed robust software systems for securely storing vast amounts of genomic and health data, and providing it in formats specific to its diverse user communities. GenoSpace for Clinical Care™ facilitates clinically actionable interpretation and report generation for precision medicine. GenoSpace for Research™ provides dynamic analysis, visualization and collaboration tools. GenoSpace for Patient Communities™ enables patient-centric exploration and advancement of personalized medicine.

GenoSpace has created an information ecosystem for 21st century genomic medicine—one that enables different participants in precision medicine to realize the potential of our ever-expanding knowledge of human disease and its treatment. Please visit www.GenoSpace.com for more information.

Company Contact:
John Quackenbush
Chief Executive Officer
GenoSpace, LLC
info@genospace.com


'/>"/>
SOURCE GenoSpace, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. GenoSpace Announces the Launch of a Cloud-Based "Information Ecosystem" for Advancing 21st-Century Personalized Medicine
2. GLM Displays Expands Its Line of Formulate Fabric Displays with the Vibe 10ft Display
3. Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
4. Leading Chemical Manufacturer Expands Biobased Offering through Unique Distribution of Proven Green Spill Absorbent
5. Defying Industry Trends, BBK Worldwide Expands Ownership From Within
6. Abacus International Expands Annual Partnership With HealthEconomics.Com
7. Personal Genome Diagnostics Inc. Licenses Genome-Mapping Technology from Johns Hopkins University and Expands Its Cancer Genome Analysis Business
8. Delta Point Strengthens Management and Expands Consultancy Services with Addition of Former AstraZeneca Executive Michael Hickey
9. SAFC Expands Irvine Facility to Add Dry Powder Media Manufacturing Capabilities
10. Genomas Expands Personalized Medicine Business with Clinical Laboratory Licenses in New York, Florida, California
11. XBiotech Expands Portfolio to Include Biosimilars
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... Prairie, WI (PRWEB) , ... June 23, 2016 ... ... consultancy focused on quality, regulatory and technical consulting, provides a free webinar ... is presented on July 13, 2016 at 12pm CT at no charge. , ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration will ... to access and transact across channels. Using this ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
Breaking Biology News(10 mins):